A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabinefirinotecan in patients with metastatic pancreatic cancer (CALGB 89904).

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Kulke, MH; Niedzwiecki, D; Tempero, MA; Hollis, DR; Mayer, RJ

Published Date

  • July 15, 2004

Published In

Volume / Issue

  • 22 / 14

Start / End Page

  • 316S - 316S

Published By

Pages

  • 1

International Standard Serial Number (ISSN)

  • 0732-183X

Conference Name

  • 40th Annual Meeting of the American-Society-of-Clinical-Oncology

Conference Location

  • New Orleans, LA

Conference Start Date

  • June 5, 2004

Conference End Date

  • June 8, 2004